Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06386770

Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block

Systemic Versus Local Dexamedetomedine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block in Kidney Exploration Surgeries ,A Randomized Controlled Trial

Sponsor: Aswan University

Conditions Dexmedetomidine Erector Spinae Block

Interventions Bupivacaine Hydrochloride Dexmedetomidine Injection [Precedex] Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)

Updated 7 times since 2024 Last updated: Feb 20, 2025 Started: Jun 1, 2024 Primary completion: Feb 25, 2025 Completion: Mar 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Dexmedetomidine and Erector Spinae Block, this trial is actively recruiting participants. The trial is conducted by Aswan University and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aswan University

Data source: Aswan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aswān, Egypt